Back to Journals » Breast Cancer: Targets and Therapy » Volume 8

Are another 5 years of adjuvant aromatase inhibitor therapy needed?

Authors Mo QG, Li DQ, Zhong JH, Wei CY

Received 20 September 2016

Accepted for publication 21 September 2016

Published 14 November 2016 Volume 2016:8 Pages 207—209

DOI https://doi.org/10.2147/BCTT.S122820

Checked for plagiarism Yes

Editor who approved publication: Professor Pranela Rameshwar

Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei

Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China

*These authors contributed equally to this work

In the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.

View original paper by Leone and colleagues.



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]